Radiotherapy in Inoperable Mucoepidermoid Parotid Cancer: A Case Report

Steven Octavianus, Henry Kodrat

Abstract


Introduction: Salivary gland cancer is an uncommon malignancy in the head and neck. The most common histopathologic type in salivary gland malignancies is mucoepidermoid carcinoma (MEC). Radiotherapy has a role in salivary gland malignancy, especially in inoperable cases and postoperative settings. Definitive or postoperative radiotherapy with or without chemotherapy can improve locoregional control (LRC) in patients with parotid mucoepidermoid carcinoma.

Case Presentation: We report a case of a 77-year-old male with inoperable MEC of the right parotid, who received definitive radiotherapy. From the three-month evaluation after radiation therapy, we found a significant reduction in the tumor mass.

Conclusions: Surgery remains the treatment of choice for patients with salivary gland malignancies. Definitive radiotherapy can be a treatment modality in inoperable cases or patients who refuse surgery. Although the result is not satisfactory, radiotherapy can still give clinical benefits to patients.


Keywords


mucoepidermoid carcinoma, parotid gland, radiotherapy, salivary gland

References


Rajasekaran K, Stubbs V, Chen J, et al. Mucoepidermoid carcinoma of the parotid gland : A National Cancer Database study. Am J Otolaryngol. 2018;39(3):321-6.

Chaukar D, Vaidya AD, Walvekar R, et al. Major salivary glands. UICC Man Clin Oncol [Internet]. Oxford: John Wiley & Sons, Ltd.; 2015. p. 571–85. Available from: http://doi.wiley.com/10.1002/9781119013143.ch46

Lewis AG, Tong T, Maghami E. Diagnosis and management of malignant salivary gland tumors of the parotid gland. Otolaryngol Clin North Am. 2016;49:343–80.

Cerda T, Shan X, Vignot S, et al. A rationale for chemoradiation ( vs radiotherapy ) in salivary gland cancers ? On behalf of the REFCOR ( French rare head and neck cancer network ). Crit Rev Oncol / Hematol. 2014;91(2):142-58.

Grégoire V, Ang K, Budach W, et al. Delineation of the neck node levels for head and neck tumors: A 2013 update. DAHANCA, EORTC, HKNPCSG, NCIC CTG, NCRI, RTOG, TROG consensus guidelines. Radiother Oncol. 2014;110:172–81

Piram L, Frédéric-Moreau T, Bellini R, et al. Proposition de délinéation des volumes cibles tumoraux et sélection des aires ganglionnaires des cancers de la glande parotide. Cancer/Radiothérapie. 2019;23:255–63.

Brouwer CL, Steenbakkers RJHM, Bourhis J, et al. CT-based delineation of organs at risk in the head and neck region: DAHANCA, EORTC, GORTEC, HKNPCSG, NCIC CTG, NCRI, NRG Oncology and TROG consensus guidelines. Radiother Oncol. 2015;117:83–90.

Cox JD, Stetz JA, Pajak TF. Toxicity criteria of the Radiation Therapy Oncology Group (RTOG) and the European organization for research and treatment of cancer (EORTC). Int J Radiat Oncol Biol Phys. 1995;31:1341–6.

Licitra L, Grandi C, Prott FJ, et al. Major and minor salivary glands tumours. Crit Rev Oncol Hematol. 2003;45:215–25.

Guzzo M, Locati LD, Prott FJ, et al. Major and minor salivary gland tumors. Crit Rev Oncol Hematol. 2010;74:134–48.

Ries LAG, Keel GE, Horner MD. SEER Survival Monograph Cancer Survival Among Adults : U . S . SE E R Program , 1988 -2001 Patient and Tumor Characteristics. 2007;1988–2001.

Battermann JJ, Breur K, Hart GA, van Peperzeel HA. Observations on pulmonary metastases in patients after single doses and multiple fractions of fast neutrons and cobalt-60 gamma rays. Eur J Cancer. 1981;17:539–48.

Pfister DG, Spencer S, Adelstein D, et al. Head and Neck Cancers, Version 2.2020, NCCN Clinical Practice Guidelines in Oncology. J Natl Compr Canc Netw. 2020;18(7):873-98.

Terhaard CHJ, Lubsen H, Van der Tweel I, et al. Salivary gland carcinoma: independent prognostic factors for locoregional control, distant metastases, and overall survival: results of the Dutch head and neck oncology cooperative group. Head Neck. 2004;26:681–93.

Pignon JP, Maître A le, Maillard E, Bourhis J. Meta-analysis of chemotherapy in head and neck cancer (MACH-NC): An update on 93 randomised trials and 17,346 patients. Radiother Oncol. 2009;92:4–14.

Blanchard P, Baujat B, Holostenco V, et al. Meta-analysis of chemotherapy in head and neck cancer (MACH-NC): A comprehensive analysis by tumour site. Radiother Oncol. 2011;100:33–40.

Gebhardt BJ, Ohr JP, Ferris RL, et al. Concurrent chemoradiotherapy in the adjuvant treatment of high-risk primary salivary gland malignancies. Am J Clin Oncol. 2018;41:888–93.

Chen AM, Bucci MK, Quivey JM, et al. Long-term outcome of patients treated by radiation therapy alone for salivary gland carcinomas. Int J Radiat Oncol Biol Phys. 2006;66:1044–50.

Chen AM, Garcia J, Lee NY, et al. Patterns of nodal relapse after surgery and postoperative radiation therapy for carcinomas of the major and minor salivary glands: what is the role of elective neck irradiation? Int J Radiat Oncol Biol Phys. 2007;67:988–94.

Orlandi E, Sanguineti G, Fallai C. Salivary Gland Tumors: Radiotherapy. In: Licitra L, Locati LD, editors. Salivary Gland Cancer [Internet]. Cham: Springer International Publishing; 2019. p. 159–95. Available from: http://link.springer.com/10.1007/978-3-030-02958-6

Spratt DE, Salgado LR, Riaz N, et al. Results of photon radiotherapy for unresectable salivary gland tumors: is neutron radiotherapy’s local control superior? Radiol Oncol. Poland; 2014;48:56–61.

Timoshchuk MA, Dekker P, Hippe DS, et al. The efficacy of neutron radiation therapy in treating salivary gland malignancies. Oral Oncol. 2019;88:51–7.

Bhide SA, Miah A, Barbachano Y, et al. Radical radiotherapy for treatment of malignant parotid tumours: A single centre experience 1995–2005. Br J Oral Maxillofac Surg. 2009;47:284–9.

Rosenberg L, Weissler M, Hayes DN, et al. Concurrent chemoradiotherapy for locoregionally advanced salivary gland malignancies. Head Neck. 2012;34:872–6.


Full Text: PDF

DOI: 10.33371/ijoc.v15i2.784

Article Metrics

Abstract view : 75 times
PDF - 56 times

Refbacks

  • There are currently no refbacks.


Copyright (c) 2021 Indonesian Journal of Cancer

Creative Commons License
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.